ABSTRACT
The main objective of this study is to analyse the clinical efficacy of medium-term telerehabilitation in the recovery of patients with Long COVID using ReCOVery APP, administered in the Primary Health Care (PHC) setting. The second objective is to identify significant patterns associated with an improvement in their quality of life predicted by other study variables. To this end, a randomised clinical trial was conducted with two parallel groups of a total of 100 patients with Long COVID. The control group continued with their usual treatment (TAU), established by their primary care physician. The intervention group, in addition to continuing with their TAU, attended three sessions based on motivational methodology and used ReCOVery APP for six months. The main variable was quality of life. The results of this study concluded that ReCOVery APP was not significantly more effective in improving the quality of life of patients with Long COVID. There was low adherence of participants. However, linear regression analyses revealed significant patterns of improvement in overall quality of life and mental health predicted by time of use of the APP and the personal construct of self-efficacy. In addition, all participants significantly improved their physical and mental health over the duration of the intervention. In conclusion, meaningful use of the ReCOVery APP may contribute to improving the quality of life of patients with Long COVID, but strategies to improve adherence need to be encouraged.
Trial Registration No ISRCTN91104012.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ISRCTN91104012
Funding Statement
This work is supported by grant number PI21/01356 from the Instituto de Salud Carlos III. In adittion, This work was supported by the Aragonese Primary Care Research Group (GAIAP, B21_23R).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was granted by the Aragon Clinical Research Ethics Committee (PI21/454),
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos